Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 39kWORD 9k
11 June 2020
Priority question for written answer
to the Commission
Rule 138
Aldo Patriciello (PPE)
 Subject: Transport of radiopharmaceuticals in the European Union

On the 22 April 2020, the Commission received a letter signed by 25 MEPs requesting support for the transport of radiopharmaceuticals in the European Union.

Radiopharmaceuticals are crucial for providing CT scans for COVID-19 patients (SPECT/CT and PET/CT imaging), as well as for fragile patient populations, such as cancer and cardiac patients.

The shelf life of these radioactive materials is extremely limited, and measured in hours and days. This means that in over 90 % of cases in the EU the time between the patient dose being ordered, produced, and shipped, and the actual diagnosis or therapeutic test is 24 hours.

Currently the number of border checks has substantially increased, and the administrative requirements are sometimes hard to follow and comply with.

Can the Commission take account of these issues, adopt a clear stance against the difficulties in shipping these vital materials between Member States, and facilitate procedures for the entire production and distribution chain?

Last updated: 16 June 2020Legal notice - Privacy policy